Principal Employer shall submit an annual return for the year ending 31 December to the concerned Registering Officer as per the given format. This covers establishment as well as principal employer particulars, nature of work, location of work, employee details, date of overtime worked, and payment particulars.

2025年1月28日 · The CLL international prognostic index (CLL-IPI) integrates genetic, biological, and clinical variables to identify distinct risk groups of patients with CLL. The CLL-IPI retains its significance in the era of targeted agents, but the overall prognosis of CLL patients with high-risk stages has improved.

2025年2月20日 · 慢性淋巴细胞白血病（CLL）是一种成熟 B 淋巴细胞克隆增殖性肿瘤，临床表现外周血淋巴细胞增多、 肝脾及淋巴结肿大，并累及淋巴系统以外其他器官，晚期可表现为 骨 髓 衰 竭。 CLL多发生于老年患者中，并且具有高度可变的临床病程。 BTK抑制剂、BCL2抑制剂和CD20单抗等疗法及其不同的两药甚至三药联合方案显著改善了CLL的预后，但最佳顺序仍有待确定，尤其是对 BTK 和 BCL2 抑制剂双重耐药的患者存在较大挑战。 《American Journal of …

2023年4月4日 · Richter转化，即CLL向高级别淋巴瘤(大b细胞淋巴瘤[90%]和霍奇金淋巴瘤[10%])转化，发生于多达10%的CLL患者，发生Richter转化的CLL患者的中位总生存期约为3 ~ 4个月。

2022年7月12日 · 当排除CLL伴Richter转化、CLL伴幼淋细胞增多、MCL母细胞变异型、MZL伴幼淋细胞增多、毛细胞白血病变异型（HCL-v），且外周血幼淋细胞占淋巴细胞比例≥55%，则可诊断为B幼淋巴细胞白血病（B-PLL）。

慢性淋巴细胞白血病（CLL）是一种CD5 + CD19 + 的成熟小B细胞在外周血、淋巴组织器官、骨髓积聚的慢性淋巴增殖性疾病，老年人多见。 化学免疫治疗（chemoimmunotherapy，CIT）仍是预后良好且可耐受的CLL患者的治疗选择之一，布鲁顿酪氨酸激酶抑制剂（BTKi）、磷脂酰肌醇3激酶抑制剂（PI3Ki）及B细胞淋巴瘤2（BCL2）抑制剂（BCL2i）等新型靶向药物使CLL的治疗进入无化疗时代，显著改善了患者的预后 [1-4]。 近年来，BTKi联合CIT、BTKi联合BCL2i±CD20 …

Chronic lymphocytic leukemia (CLL) is 10-to 20-fold less common in Han Chinese in China compared with persons of predominately European descent translating to incidences of 0.2 to 0.6 per 10E+5 population/year vs. 4.6 per 10E+5 population/year.

2019年12月3日 · Chronic lymphocytic leukemia (CLL), the most frequent type of leukemia in adults, is a lymphoproliferative disease characterized by the clonal expansion of mature CD5+ B cells in peripheral blood, bone marrow, and secondary lymphoid tissues.

2019年3月14日 · Recent evidence suggests that complex karyotype (CK) defined by the presence of ≥3 chromosomal aberrations (structural and/or numerical) identified by using chromosome-banding analysis (CBA) may be relevant for treatment decision …

慢性淋巴细胞白血病 (cll) 患者有四分之三以上大于 60 岁，儿童期患病极其罕见。cll 是北美和欧洲最常见的 白血病 类型。该病在日本和东南亚以及生活在美国的日本和东南亚血统的人中很少见，这表明遗传学在发病中起到一定的作用。

The coexistence of myeloproliferative neoplasm (MPN) with lymphoid neoplasm (LN) is relatively rare event and among reported single case associations, the most represented LN is chronic lymphocytic leukemia (CLL).

CLL/SLL是主要发生在中老年人群的一种具有特定免疫表型特征的成熟B淋巴细胞克隆增殖性肿瘤，以淋巴细胞在外周血、骨髓、脾脏和淋巴结聚集为特征。 二、诊断、分期、预后及鉴别诊断1．诊断： 达到以下3项标准可以诊断：①外周血单克隆B淋巴细胞计数≥5×109/L。 ②外周血涂片特征性的表现为小的、形态成熟的淋巴细胞显著增多，其细胞质少、核致密、核仁不明显、染色质部分聚集，并易见涂抹细胞；外周血淋巴细胞中不典型淋巴细胞及幼稚淋巴细胞<55%。 ③典 …

2020年6月24日 · Population-wide studies have shown that chronic lymphocytic leukemia (CLL) shows remarkable geographic and ethnic variations. CLL is the most common leukemia in the United States (> 30% of all leukemia) and the least common leukemia in …

CLL, also known as CLL / SLL or chronic lymphocytic leukemia/small lymphocytic lymphoma, is a blood cancer. Specifically, it is a cancer of a type of white blood cell called the B-lymphocyte. In CLL there is a progressive accumulation of too many mature lymphocytes, which are usually monoclonal or genetically identical.

Chronic Lymphocytic Leukemia (CLL) • A blood cancer in which large numbers of abnormal white blood cells are produced • Symptoms include fatigue, fever, chills, swollen lymph nodes

2024年2月21日 · Chronic lymphocytic leukemia (CLL) is a lifelong condition for most people. This type of cancer is not curable, but many people can live for many years. There are...

2023年11月30日 · Putting it all together, the sequence "XXV XXVIII XXIX XXVII XXIV XXV" in Arabic numerals is: 25, 28, 29, 27, 24, 25. Each Roman numeral set is converted to its corresponding Arabic numeral value, and the sequence is read as a list of these numbers.

罗马数字到数字的转换计算器以及如何转换。

Write any Roman Numeral into the box and hit the button to convert.

2024年7月17日 · Presidential Disability Under the Twenty-Fifth Amendment: Constitutional Provisions and Perspectives for Congress